This study offers a valuable methodological advance by introducing a gene panel selection approach that captures combinatorial specificity to define cell identity. The findings address key limitations ...
The FDA has accepted Pharming Group’s supplemental new drug application for leniolisib in treating activated phosphoinositide 3-kinase delta syndrome, or APDS, in children aged 4 to 11 years, ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback